ASCO 2026 preview – Pumitamig looks similar to ivonescimab again
First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
AACR 2026 – Moderna touts first-line data
The IDO/PD-L1 project mRNA-4359 shows early hints in first-line melanoma.
Henlius starts a pivotal journey to catch Pfizer
The Chinese company will start the first of four pivotal trials of its PD-L1 ADC in April.
AbbVie and RemeGen’s bispecific goes pivotal
Chinese trials in first-line NSCLC and colorectal cancer are imminent.
The relentless march of VEGF bispecifics
Two new pivotal Chinese first-line trials have started in lung cancer.
Pfizer mimics pumitamig in gastroesophageal cancers
The company will start a phase 2/3 trial of PF-08634404 in March.
Pumitamig pivotal trials come in pairs
Bristol will test the bispecific in two new lung indications.
Huabo goes pivotal with bispecific VEGF trap
The company takes a PD-L1 x VEGF asset into phase 3.
